Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

VX-407

Small molecule · developed by VERTEX PHARMACEUTICALS INC / MA

Phase 2 Most advanced trial

VRTX Developer

2 Registered trials

What is VX-407?

VX-407 is an oral agent studied in autosomal dominant polycystic kidney disease (ADPKD).

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Renal & urology
Developer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07161037	Phase 2	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Active not recruiting	VRTX
NCT07868926	Phase 1	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Not yet recruiting	VRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

More from VERTEX PHARMACEUTICALS INC / MA

Deutivacaftor FDA approved Elexacaftor FDA approved Exagamglogene Autotemcel FDA approved Ivacaftor FDA approved Suzetrigine FDA approved Tezacaftor FDA approved Vanzacaftor FDA approved Inaxaplin Phase 2/3 Povetacicept Phase 2/3 VX-017 Phase 3 VX-118 Phase 1 VX-264 Phase 1/2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the VRTX page.

Follow VRTX, the company behind VX-407

See VRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z